My take on Ergynuit Sommeil Profond: a melatonin-free formula worth considering for a supervised trial, but I would not buy it specifically to increase deep sleep. The GABA dose is close to those used in some human research. That demonstrates neither the blend’s effectiveness nor a guaranteed reduction in nighttime awakenings.
This review is based on documentary research, with no claim of personal testing and no affiliate link. The useful question is simple: do the ingredients, doses and outcomes studied justify the price? The product name already does the marketing. Now for the evidence.
What exactly is in two capsules?
The official English-language Nutergia information sheet, accessed for this analysis, details the formula. As the French product page was difficult to use, this manufacturer source serves as the documentary reference. Still, check the French label on the batch you buy.
The amounts are for two capsules, the stated daily serving:
| Active ingredient | Amount | Reference intakes |
|---|---|---|
| Valerian extract | 300 mg | Not established |
| GABA | 250 mg | Not established |
| Common poppy extract | 20 mg | Not established |
| Elemental magnesium | 56 mg | 15% |
| Zinc | 6 mg | 60% |
| Copper | 0.15 mg | 15% |
| Vitamin B6 | 0.28 mg | 20% |
| Methylated vitamin B9 | 40 µg | 20% |
| Methylated vitamin B12 | 0.5 µg | 20% |
The ingredients include Valeriana officinalis, GABA, magnesium hydroxide and bisglycinate, zinc and copper gluconates, Papaver rhoeas, magnesium salts of fatty acids, pyridoxine hydrochloride, calcium L-methylfolate and methylcobalamin. The capsule shell is made of hydroxypropyl methylcellulose.
Common poppy is not California poppy. Trials on Eschscholzia therefore prove nothing about this ingredient. The formula also lacks the passionflower found in other products in the range.
GABA: a plausible dose, but still weak evidence
GABA is an inhibitory neurotransmitter: in the brain, it helps reduce neuronal excitability. But swallowing GABA is not the same as directly increasing brain GABA. Whether it crosses the blood–brain barrier in humans remains uncertain. Peripheral pathways have been proposed, without establishing the clinical mechanism.
The systematic review by Hepsomali and colleagues, published in 2020, describes the sleep evidence as very limited. It brings together small trials using varying preparations and methods. Some studies involve companies in the sector, strengthening the need for independent replication.
A trial by Byun summarised in this review included 40 adults with poor sleep, comparing 300 mg of GABA daily for four weeks with placebo. There was a favourable signal for time to fall asleep. However, several other outcomes showed no between-group difference, including stage N3 and time awake after falling asleep.
At 250 mg, Ergynuit is close to the 300 mg tested, but that proximity does not establish equivalence. The GABA source, formulation and other ingredients differ. A dose close to one used in a trial is not a trial of the product.
Another human study published by Yamatsu and colleagues reports faster sleep onset and more non-REM sleep after oral GABA. Non-REM sleep includes several stages: it does not automatically mean more deep sleep. The authors’ affiliations included Pharma Foods International.
My takeaway is therefore a defensible hypothesis for sleep onset, with low confidence. The argument becomes much weaker when it promises nights without awakenings or extra N3 sleep.
Valerian: 300 mg does not tell you everything about the extract
Valerian has a longer history of human research. The European Medicines Agency recognises well-established medicinal use for certain dry ethanolic preparations for sleep disorders and mild nervous tension. Other preparations fall under traditional use.
This distinction matters: the assessment concerns medicines and defined preparations with specific requirements. It does not automatically validate a supplement displaying the same botanical name.
The NIH overview of valerian describes, among others, a trial in 128 volunteers using 400 mg of aqueous extract and another in 121 people with insomnia using 600 mg of a standardised preparation for 28 days. Some results were favourable, but the overall evidence remains inconclusive.
Ergynuit’s 300 mg is a lower mass than either of these examples. Still, I would not automatically call it underdosed: without comparable plant-to-extract ratios, solvents and standardisation, comparing milligrams becomes misleading. Two extracts of the same weight can have different chemical profiles.
The official information sheet consulted does not provide enough detail to establish this equivalence. That is a transparency limitation worth knowing before buying, not proof of ineffectiveness. Asking the manufacturer for this information would add more value than another adjective about the blend’s strength.
Common poppy and micronutrients: what evidence supports the doses included?
To compare the nine active ingredients without turning a biological function into a clinical promise, here is what the sources consulted support:
| Active ingredient in the formula | Relevant comparison | What we can conclude |
|---|---|---|
| Common poppy, 20 mg | No relevant controlled human trial identified for this extract and dose | No quantifiable benefit can be attributed |
| Magnesium, 56 mg | 320–729 mg/day in the trials in the 2021 review | Does not establish a sleep-inducing effect |
| Zinc, 6 mg | No effective standalone dose established here for treating insomnia | Nutritional role, not evidence of deep sleep |
| Copper, 0.15 mg | No relevant clinical comparison identified at this dose | No demonstrated nighttime effect |
| B6, 0.28 mg | Nutritional intake, not a validated insomnia protocol | No established additional benefit |
| B9, 40 µg | Methylated form with no direct sleep evidence at this dose | Methylation does not mean sedation |
| B12, 0.5 µg | No established sleep-inducing benefit at this dose | No defensible clinical promise |
The absence of an identified trial does not establish that an ingredient is useless in every situation. Above all, it prevents us from crediting it with a specific number of minutes gained or awakenings avoided.
For magnesium, the NCCIH highlights the weakness of the research: a review of three studies involving 151 older participants suggested a possible benefit for sleep onset, but the evidence was too poor in quality to draw firm conclusions. This does not validate the blend’s 56 mg. The review by Mah and Pitre reports intakes of 320–729 mg of elemental magnesium daily, as oxide or citrate, for 20 days to eight weeks. These amounts, far higher than those in Ergynuit, are research doses, not targets to copy through self-medication. Increasing the number of capsules would also increase every other active ingredient, without established safety or effectiveness.
Addressing inadequate intake requires considering diet, medical context and total magnesium. The presence of bisglycinate does not mean that all the magnesium comes from that form. Our analysis of magnesium bisglycinate and its evidence explains why form, elemental dose and need must be considered separately.
Does the formula really increase deep sleep?
In the sources consulted, I did not identify a published controlled trial evaluating the complete Ergynuit Sommeil Profond formula against placebo with an objective measurement of N3. Confidence in this claim therefore remains low.
Three outcomes must remain distinct: falling asleep faster, feeling more rested and spending more time in deep sleep. A positive study on the first does not demonstrate the other two. Nor does a blend gain extra effectiveness simply because each ingredient has a biological rationale.
Customer reviews can flag digestive discomfort, difficulty swallowing or a perceived benefit. They cannot separate the product’s effect from natural fluctuations, expectations and changes in habits. A good week after buying it is not a placebo-controlled trial.
If your concern mainly comes from a watch score, start with the guidance on deep sleep duration · FR. Buying a supplement to correct an uncertain estimate risks adding an expense without solving the original problem.
Daily price and value for money
The official French Nutergia website lists €16.90 for 60 capsules when accessed on 21 October 2026. At two a day, that covers 30 days and costs €0.56 per day, rounded, excluding delivery and promotions. That calculation is 16.90 divided by 30, not by 60.
This is still money spent on an uncertain benefit, even if it seems affordable. The real Toll, the hidden cost of a solution, also includes repeat purchases and time spent delaying appropriate care.
I would not compare brands by their ingredient count. A simple formula with a well-characterised preparation may be easier to assess than a longer blend. Before buying again, ask yourself whether you can observe a useful change and whether attributing it to the product remains plausible.
What alternatives fit your problem?
Persistent insomnia calls for appropriate care first. The NCCIH presents cognitive behavioural therapy for insomnia as the most strongly recommended treatment. Among other things, it addresses the behaviours and associations that maintain wakefulness in bed. A simple sleep-hygiene checklist does not replace this structured therapy.
For a shifted body clock or a clearly identified sleep-onset problem, melatonin may serve a different purpose. It provides a timing signal rather than a guarantee of deep sleep. It is not automatically a better alternative: its interactions and precautions need checking.
If the goal is nutritional, targeted correction of intake may make more sense than a nighttime blend. If the problem is an isolated tracker score with no impact on your life, the alternative may simply be to monitor that score less and focus on how you function during the day.
How do you choose between a single herb and a blend?
A properly documented valerian-only preparation makes the label easier to assess and any adverse effect easier to attribute. It does not guarantee a result either. Check the botanical name, plant part used, amount per serving, extract type and precautions specific to that product. If that information is missing, a large number on the label does not resolve the uncertainty.
The blend’s main advantage is convenience: several ingredients in one dose. It also has an experimental limitation: if your sleep changes, you will not know which ingredient contributed. This trade-off may suit some informed adults, but it demonstrates no synergy. Establishing synergy would require comparing the blend with the relevant components under controlled conditions.
Before choosing, define a single priority: the time spent waiting to fall asleep, long periods awake during the night or daytime fatigue. This avoids declaring a product effective because a secondary measure improved. It also helps you recognise failure sooner and discuss it with a professional.
If you are considering a trial: safety and a stopping rule
The manufacturer specifies two capsules a day before bed. These commercial directions are not a personalised prescription. Do not increase the dose to match an experimental GABA or valerian dose.
The official information sheet advises against using the product during pregnancy, breastfeeding or if you have epilepsy. For minors, no self-medication: professional advice and any dose adjustment are the clinician’s responsibility.
The NIH notes that valerian’s sedative effects may be additive. Avoid alcohol and have combinations with sleeping pills, anti-anxiety medicines, sedating antihistamines or other sleep products checked. Do not drive if you feel drowsy. Nausea, abdominal cramps or reduced alertness warrant stopping and seeking appropriate advice.
If you have kidney disease or take regular medication, have the entire formula checked: magnesium also has drug interactions, particularly with certain antibiotics and bisphosphonates.
To make the assessment useful, without claiming to conduct a clinical trial:
- For one week, record your estimated time to fall asleep, periods awake and how you feel on waking.
- If your pharmacist approves the trial, keep similar sleep times and do not add other supplements at the same time.
- Set a review point after two weeks. This cautious timeframe does not claim to reproduce four-week trials.
- Stop if you experience a troublesome effect. Without clear improvement, do not automatically buy more.
Seek medical advice if the problems persist or worsen. Observed breathing pauses, snoring with significant drowsiness or falling asleep at the wheel require assessment, not another box.
